Tuesday, March 22, 2011
Calif.-based Quark Pharmaceuticals, engaged in the discovery and development of RNAi-based therapeutics, has received results from a prospective randomized phase II trial, the DEGAS study. This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema (DME). There were 184 patients randomly assigned to four treatment groups; three dose levels of PF-04523655 (RTP801I-14) (0.4mg, 1mg, and 3mg) or laser. The study was designed with a primary endpoint of mean visual acuity improvements over baseline at 24 months.